J.A.Fisheret al., “Appraising Harm in Phase I Trials: Healthy Volunteers' Accounts of Adverse Events,”Journal of Law, Medicine & Ethics47, no. 2 (2019): 323-333.
2.
S.C.Chen, N.Sinaii, G.Bedarida, M.A.Gregorio, E.Emanuel, and C.Grady, “Phase 1 Healthy Volunteer Willingness to Participate and Enrollment Preferences,”Clinical Trials14, no. 5 (2017): 537-546, doi: 10.1177/1740774517722131.
3.
Chen, supra note 2.
4.
Fisher, supra note 1.
5.
Fisher, supra note 1.
6.
J. J.Różyżska, “What Makes Clinical Labour Different? The Case of Human Guinea Pigging,”Journal of Medical Ethics44, no. 9 (2018): 638-642, doi:10.1136/medethics-2017-104267.
7.
Fisher, supra note 1.
8.
A.Eaton, A.Iasonos, M.M.Gounder, E.G.Pamer, A.Drilon, D.Vulih, G.L.Smith, S.P.Ivy, D.R.Spriggs, and D.M.Hyman, “Toxicity Attribution in Phase I Trials: Evaluating the Effect of Dose on the Frequency of Related and Unrelated Toxici-ties,”Clinical Cancer Research22, no. 3 (2016): 553-559, doi: 10.1158/1078-0432.CCR-15-0339.
9.
M.Waligoraet al., “Risk and Surrogate Benefit for Pediatric Phase I Trials in Oncology: A Systematic Review with Meta-Analysis,”PLOS Medicine15, no. 2 (2018): e1002505, doi:10.1371/journal.pmed.1002505.
